Avian
Influenza (H5N1)
Oral Vaccine
Vaccine efficacy has been established in challenge studies using mice
and large animals (ferrets). Phase I clinical trials are expected by
approximately Q1 2011.
Pandemic
H1N1 (Swine
Flu) Vaccine
Animal immunogenicity established, challenge studies are expected in
2010.
Board of Directors
Richard Markham, Chairman
Mr. Markham is a Partner at Care Capital.
Prior to joining
Care Capital, among other posts, Mr. Markham was the CEO of Aventis
Pharma, the CEO of Hoechst Marion Roussel, and the President and COO of
Marion Merrell Dow, Inc. From 1973 to 1993, Mr. Markham was associated
with Merck & Co., Inc., culminating in his position as President
and COO. Mr. Markham has been a member of the board of directors and
executive committee of the Pharmaceutical Research and Manufacturers
Association, a member of the Board of Trustees of the HealthCare
Institute of New Jersey, and a member of the board of directors of
Aventis Pasteur and of Commerce Bank of Kansas City. Mr. Markham
received a B.S. in Pharmacy and Pharmacal Sciences from Purdue
University and has served as a member of the Dean’s Advisory Council of
the university. He has also been awarded an honorary Doctor of Science
degree, the university’s highest honor for achievement.
Jan Leschly
Mr. Leschly is a partner at Care Capital.
Before founding
Care Capital, Mr. Leschly was Chief Executive of SmithKline Beecham PLC
("SB") from 1994 to 2000. He joined SB as Chairman of the Worldwide
Pharmaceutical business in 1990 and was elected to the Board of
Directors in 1990. Before joining SB, Mr. Leschly served as President
and COO, Squibb Corporation. Mr. Leschly is a member of the Boards of
Directors of the American Express Company and the APM-Maersk Group.
Before his business career, Mr. Leschly made his name in professional
tennis, achieving the rank of 10th in the world in 1967. Born in
Denmark, Mr. Leschly received a Master of Science in Pharmacy from the
Copenhagen College of Pharmacy and a B.S. in Business Administration
from the Copenhagen School of Economics and Business Administration.
Michael J. Finney, Ph.D. Dr. Finney is Managing Director of Finney
Capital. He has
been a Vaxart director since 2007. He is a graduate of Harvard
College and has a PhD. in Biology from the Massachusetts Institute of
Technology. He has been a director of biotechnology companies for over
25 years.
Sean Tucker, Ph.D. Dr. Tucker founded Vaxart in 2004. Dr. Tucker
received his
Ph.D. in Immunology from the University of Washington and previously
held research and development positions of increasing responsibility at
Genteric, SyStemix, and Dow Chemical.
Management
Michael J. Finney, Ph.D. Acting
CEO Dr. Finney was a member of the Vaxart Board
of Directors for
two years before becoming Acting CEO in July 2009. He has a PhD.
in Biology from the Massachusetts Institute of Technology and was a
co-founder and CSO of MJ Research, Inc. He has been a director of
biotechnology companies for over 25 years.
Sean Tucker, Ph.D. Founder, VP
Research,
and CSO Dr. Tucker’s expertise is in oral
administration of
gene-based vaccines and mucosal immunology. He has previously served as
a principal investigator on an NIH SBIR grant for the purpose of
exploring oral delivery (salivary gland) as a site for HIV vaccine
delivery. Dr. Tucker previously held research and development positions
of increasing responsbility at Genteric, SyStemix, and Dow Chemical.
Recently published articles include: Mol Therapy 8:392 and Vaccine
22:2500
George Trager, MBA Director,
Product
Development Mr. Trager served as Associate
Director, Formulation and Purification Development during his nine
years with MedImmune Vaccines. His team led the development of
refrigerator-stable FluMist. Mr. Trager has also worked for
Matrix Pharmaceuticals, Genelabs and Xoma.
Ciaran Scallan, Ph.D. Senior
Scientist Dr. Scallan’s expertise is in molecular
virology and
assesment of immune responses to viral vectors. Recently published
articles include: Blood 102:3919, Blood 102:2021 and Blood 107:1810
Key Advisors
Prof. Richard Whitley, M.D. Director, Division of Pediatric Infectious
Diseases, and
Co-Director, Center for Emerging Infections and Emergency Preparedness,
University of Alabama at Birmingham.
Prof.
Harry
Greenberg,
M.D. Dr. Greenberg is a Professor at Stanford
Department of
Medicine.
He brings expertise in pathogenic viruses that infect the
gastrointestinal track. Dr. Greenberg was the Chief Scientific
officer at Aviron (now MedImmune Vaccines) where he played a key role
in bringing the live attenuated influenza vaccine to licensure.
Copyright
2004-2010,
Vaxart,
Inc. All rights reserved.